Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Gets Regen Med Assets, Acelity Gets Cash Boost Post-IPO Dump

Executive Summary

Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Kinetic Concepts continues wound care diversification with Systagenix buy

In a bid to counter increasing pressure on its core negative pressure wound care business, Kinetic Concepts is expanding its portfolio by agreeing to buy UK firm Systagenix for $485m. The deal, which is expected to close in the fourth quarter, is a “major step…towards increased revenue diversification and geographic expansion,” Kinetic said.

Kinetic seals $1.7bn deal with LifeCell and tags on new biosurgery division

Advanced wound care company Kinetic Concepts is to buy tissue repair product manufacturer LifeCell in a cash transaction worth $1.7bn, a move that will enable Kinetic to consolidate its presence in the fast-growing biosurgery market.

Topics

UsernamePublicRestriction

Register

MT104236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel